Integrating Pharmacogenomics into the Broader Construct of Genomic Medicine: Efforts by the ClinGen Pharmacogenomics Working Group (PGxWG).

Pharmacogenomics (PGx) is focused on the relationship between an individual's genetic makeup and their response to medications, with the overarching aim of guiding prescribing decisions to improve drug efficacy and reduce adverse events. The PGx and genomic medicine communities have worked independently for over 2 decades, developing separate standards and terminology, making implementation of PGx across all areas of genomic medicine difficult. To address this issue, the Clinical Genome Resource (ClinGen) Pharmacogenomics Working Group (PGxWG) was established by the National Institutes of Health (NIH)-funded ClinGen to initially create frameworks for evaluating gene-drug response clinical validity and actionability aligned with the ClinGen frameworks for evaluating monogenic gene-disease relationships, and a framework for classifying germline PGx variants similar to the American College of Medical Genetics (ACMG) and Association of Molecular Pathology (AMP) system for interpretation of disease-causing variants.

Dipeptidyl peptidase-4 inhibitor linagliptin reduces inflammatory response, ameliorates tissue edema formation, and improves survival in severe sepsis.

Background: Excessive inflammation in sepsis causes microvascular dysfunction associated with organ dysfunction and high mortality. The present studies aimed to examine the therapeutic potential of linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor in a clinically relevant polymicrobial sepsis model in mice.

Methods: Sepsis was induced by cecal ligation and puncture (CLP).

Seasonal fluctuation of insecticide resistance mutation frequencies in field populations of Anopheles and Culex species in Korea.

Members of the Anopheles Hyrcanus Group, Culex pipiens complex, and Culex tritaeniorhynchus are prevalent vector species in the Republic of Korea (ROK), transmitting Plasmodium vivax and various arboviruses. Extensive use of insecticides to control these mosquitoes has led to insecticide resistance. In this study, we monitored 3 target site mutations associated with insecticide resistance (kdr for pyrethroid resistance, ace1 for organophosphate resistance, and rdl for phenylpyrazole resistance) in these mosquito groups over four consecutive years to understand the seasonal dynamics of resistance in different areas with distinct ecological characteristics.

PGxQA: A Resource for Evaluating LLM Performance for Pharmacogenomic QA Tasks.

Pharmacogenetics represents one of the most promising areas of precision medicine, with several guidelines for genetics-guided treatment ready for clinical use. Despite this, implementation has been slow, with few health systems incorporating the technology into their standard of care. One major barrier to uptake is the lack of education and awareness of pharmacogenetics among clinicians and patients.

A Comprehensive Bibliometric Analysis: Celebrating the Thirtieth Anniversary of the Pacific Symposium on Biocomputing.

The 2025 Pacific Symposium on Biocomputing (PSB) represents a remarkable milestone, as it is the thirtieth anniversary of PSB. We use this opportunity to analyze the bibliometric output of 30 years of PSB publications in a wide range of analyses with a focus on various eras that represent important disruptive breakpoints in the field of bioinformatics and biocomputing. These include an analysis of paper topics and keywords, flight emissions produced by travel to PSB by authors, citation and co-authorship networks and metrics, and a broad assessment of diversity and representation in PSB authors.